Cryo-expansion microscopy has enabled researchers to visualise the three-dimensional organisation of cytotoxic T lymphocytes ...

Researchers have discovered that DNA wrapped around nucleosomes exists in multiple partially open states rather than simply ...

Researchers have developed a dual-mechanism compound that significantly extended survival in preclinical pancreatic cancer ...

Drug Target Review has launched an updated website to improve access to content across early-stage drug discovery, alongside ...

Researchers at the University of Houston have identified epithelial stress signalling as a key driver of Crohn's disease and ...

VIB-VUB researchers have developed a patient-relevant lung adenocarcinoma model combined with SEPARATE-Seq technology to ...

For years, AI drug discovery has been judged on benchmark performance. Now, a set of studies shows what happens when those ...

Insilico Medicine’s AI-designed drug for idiopathic pulmonary fibrosis (IPF), Rentosertib, has been granted an official name by USAN. This is the first drug where both the target and compound were ...

Rare disease research operates under conditions of extreme complexity. These pressures are driving new approaches to evidence ...

As AI drug discovery enters 2026, the industry faces a pivotal year of clinical tests, regulatory clarity, and market consolidation. Here, Dr Raminderpal Singh examines where AI is delivering ...

Can targeting both regulatory and inflammatory pathways change how we treat neurodegenerative disease? Coya Therapeutics is testing that idea with its IL-2 and GLP-1 receptor agonist combination.

Oral peptide-based drugs are set to revolutionise the pharmaceutical industry, overcoming the long-standing challenge of poor bioavailability. Santosh Kulkarni reveals how new breakthroughs in drug ...